The new oral anticoagulants and the future of haemostasis laboratory testing

Biochemia Medica

Volumn 22, Issue 3, 2012, Pages 329-341

  Favaloro, Emmanuel J ^a   Lippi, Giuseppe ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Anti thrombotics; Anticoagulants; Coagulation; Dabigatran; Haemostasis; Laboratory tests; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN; LUPUS ANTICOAGULANT; RIVAROXABAN;

ANTICOAGULANT THERAPY; ASSAY; BLOOD CLOTTING TIME; CHROMOGENIC ANTI XA ASSAY; DILUTE RUSSELL VIPER VENOM TIME ASSAY; ECARIN CLOTTING TIME; EMBOLISM; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; STANDARD; THROMBIN TIME; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84867255276     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/bm.2012.035     Document Type: Review

References (48)

1. Favaloro EJ, Lippi G. Coagulation Update: What's new in hemostasis testing? Thromb Res 2011;127 Suppl 2:S13-6.
2. Lippi G, Favaloro EJ, Franchini M, Guidi GC. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 2009;35:9-22.
3. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants-the present and the future. Pathology 2011;43:682-92.
4. Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost 2011;37:252-66.
5. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008;34:747-61.
6. Favaloro EJ, Adcock DM. Standardization of the INR: how good is your laboratory's INR and can it be improved? Semin Thromb Hemost 2008;34:593-603.
7. Favaloro EJ, McVicker W, Hamdam S, Hocker N. Improving the harmonisation of the International Normalized Ratio (INR): Time to think outside the box? Clin Chem Lab Med 2010;48:1079-90.
8. Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008;34:604-11.
9. Favaloro EJ. Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost 2010;36:458-67.
10. Favaloro EJ, Funk (Adcock) DM, Lippi G. Preanalytical variables in coagulation testing associated to diagnostic errors in hemostasis. Lab Medicine 2012;43:54-60.
11. Cuker A. Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty. Semin Thromb Hemost 2012;38:593-9.
12. Lassila R, Antovic JP, Armstrong E, Baghaei F, Dalsgaard-Nielsen J, Hillarp A, et al. Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia. Semin Thromb Hemost 2011;37:328-36.
13. Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real-world issues. Semin Thromb Hemost 2011;37:653-63.
14. Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost 2012;38:31-7.
15. Prechel M, Walenga JM. Heparin-Induced Thrombocytopenia: An Update. Semin Thromb Hemost 2012;38:483-96.
16. Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome. Semin Thromb Hemost 2012;38:339-47.
17. Levi M. Antithrombotic management of atrial fibrillation. Semin Thromb Hemost 2009;35:525-6.
18. Lippi G, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype? Clin Chem Lab Med 2009;47:503-15.
19. Božina N. The pharmacogenetics of warfarin in clinical practice. Biochem Med 2010;20:33-44.
20. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007;147:755-65.
21. Favaloro EJ, Bonar R, Sioufi J, Wheeler M, Low J, Aboud M, et al (on behalf of the RCPA QAP in Haematology). An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. Pathology 2005;37:234-8.
22. Walenga JM, Jackson CM, Kessler CM. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Semin Thromb Hemost 2011;37:322-7.
23. Favaloro EJ, Bonar R, Aboud M, Low J, Sioufi J, Wheeler M, et al (on behalf of the RCPA QAP in Haematology). How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? The laboratory perspective. Lab Hematol 2005;11:157-62.
24. Samama MM, Guinet C. Review: Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49:761-72.
25. Ansell J. Warfarin versus new agents: interpreting the data. Hematology Am Soc Hematol Educ Program 2010;2010:221-8.
26. Levy JH, Key NS, Azran MS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology 2010;113:726-45.
27. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010;115:15-20.
28. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: For and against? Clin Chem Lab Med 2011;49:755-7.
29. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012;38:16-22.
30. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, et al; Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105: 371-8.
31. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
32. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985-97.
33. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138-43.
34. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003 Jul-2004 Aug;33:173-83.
35. Samama MM, Martinoli J-L, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
36. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012;38:178-84.
37. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011;9:133-9.
38. Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008;100:350-5.
39. Favaloro EJ, Wong R. Laboratory testing for the Antiphospholipid Syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011;49:447-61.
40. Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory Identification of Lupus Anticoagulants. Semin Thromb Hemost 2012;38:375-84.
41. Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012;38:23-30.
42. Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost 2012;38:7-15.
43. Franchini M, Mannucci PM. Thrombin and cancer: from molecular basis to therapeutic implications. Semin Thromb Hemost 2012;38:95-101.
44. Mina A, Favaloro EJ, Mohammed S, Koutts J. A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul Fibrinolysis 2010;21:152-7.
45. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 2010;21:459-63.
46. Bonar R, Favaloro EJ, Adcock DM. Quality in coagulation and haemostasis testing. Biochem Med 2010;20:184-99.
47. Favaloro EJ, Lippi G. Laboratory reporting of hemostasis assays: the final post-analytical opportunity to reduce errors of clinical diagnosis in hemostasis? Clin Chem Lab Med 2010;48:309-21.
48. Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL. Clin Chem Lab Med, DOI: 10.1515/ cclm-2012-0327, July 2012.